Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity

Mol Med Today. 1997 Jan;3(1):24-30. doi: 10.1016/S1357-4310(96)10054-X.


Epstein-Barr virus (EBV) is a latent herpesvirus that is associated with a number of tumors. EBV-infected cells show three patterns of latency ranging from type 1, where only one EBV-encoded antigen is expressed, to type 3, where all nine latent cycle proteins encoded by EBV are expressed. Malignancies exhibiting the type 3 latency pattern are highly immunogenic and occur only in immunocompromised patients. It has recently been shown that adoptive immunotherapy with EBV-specific cytotoxic T lymphocytes is an effective therapy for such tumors. Immunotherapy strategies and approaches to increase tumor immunogenicity are now being evaluated in tumors expressing type 2 latency.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Animals
  • Herpesviridae Infections / immunology
  • Herpesviridae Infections / therapy*
  • Herpesvirus 4, Human / genetics
  • Herpesvirus 4, Human / immunology*
  • Humans
  • Immunocompromised Host
  • Immunotherapy
  • Lymphoproliferative Disorders / immunology
  • Lymphoproliferative Disorders / virology*
  • Tumor Virus Infections / immunology
  • Tumor Virus Infections / therapy*
  • Virus Latency